DOSAGE INDEX / SINGLE
CJC-1295 DAC
Research, reported schedules and supply planning.
Explore CJC-1295 DAC human research, GH and IGF-1 findings, formulation differences, FDA safety concerns and the limits of claimed physical benefits.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
Reported example 1
- Amount
- 2 mg per week
- Frequency
- Once weekly
- Cycle / observation period
- 8–12 weeks
- Route / research model
- Subcutaneous
The 5 mg vial page describes a different amount and frequency. Vial size alone does not justify a different biological regimen.
Reported example 2
- Amount
- 300–1,000 micrograms per administration
- Frequency
- Twice weekly
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
This differs from the once-weekly schedule on the 2 mg vial page.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 2 mg | Enter a total |
| 5 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Teichman and colleagues conducted two randomized, double-blind, placebo-controlled studies lasting 28 and 49 days in healthy adults aged 21 to 61. After a single administration, the abstract reports mean GH increases of two- to ten-fold lasting at least six days and mean IGF-I increases of 1.5- to three-fold for nine to eleven days. The estimated CJC-1295 half-life was 5.8 to 8.1 days. [1]
- FDA's safety-risk page flags potential immunogenicity and characterization concerns for compounded CJC-1295, and reports serious adverse events associated with it, including increased heart rate and systemic vasodilatory reactions. The agency describes the clinical data as limited. [5]
- The Teichman abstract reports no serious adverse reactions in its two trials. Keep that bounded observation separate from a general safety guarantee. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 44 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Teichman et al., 2006: sustained GH and IGF-I responses
- Ionescu and Frohman, 2006: GH pulsatility
- Jetté et al., 2005: albumin-linked analogue research
- FDA, December 2024: advisory-committee review materials
- FDA: bulk-substance safety concerns
- Journal of Clinical Endocrinology & MetabolismFurther reading · Listed in reference bibliography.
- Clinical Pharmacology & TherapeuticsFurther reading · Listed in reference bibliography.
- Growth Hormone & IGF Research (ScienceDirect)Further reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- MedlinePlusGeneral guidance · Listed in reference bibliography.
- Endocrine ReviewsFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- NIBSCFurther reading · Listed in reference bibliography.
- FDA CJC-1295-Related Substances Evidence Review Official review corroborating the exact repeat-group study-day schedulesRegulatory / product information · Listed in reference bibliography.
- StatPearls (NCBI Bookshelf) — Brinkman JE et al. Physiology, Growth HormoneFurther reading · Listed in reference bibliography.
- CDC Pink Book (Chapter 6) — Vaccine administration: subcutaneous route (angle/site; no aspiration)General guidance · Listed in reference bibliography.
- Johns Hopkins Arthritis Center — How to give a subcutaneous injection (patient guidance)General guidance · Listed in reference bibliography.
- StatPearls (NCBI Bookshelf) — Regular Insulin: subcutaneous administration and site rotationFurther reading · Listed in reference bibliography.
- Immunize Canada — How to Vaccinate: Best Practices (subcutaneous injection technique)Further reading · Listed in reference bibliography.
- Postgrad Med J (2006) — Ayuk J, Sheppard MC. Growth hormone and its disordersFurther reading · Listed in reference bibliography.
- Am J Physiol Endocrinol Metab (2006) — Alba M et al. Once-daily CJC-1295 normalizes growth in GHRH knockout mouseFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.